These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15462696)

  • 1. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis.
    Balkrishnan R; Rajagopalan R; Shenolikar RA; Camacho FT; Whitmire JT; Anderson RT
    Curr Med Res Opin; 2004 Oct; 20(10):1633-40. PubMed ID: 15462696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis.
    Balkrishnan R; Rajagopalan R; Shenolikar RA; Camacho FT; Anderson RT
    Curr Med Res Opin; 2006 Mar; 22(3):551-9. PubMed ID: 16574038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007; 29 Spec No():1306-15. PubMed ID: 18046930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007; 29 Spec No():1294-305. PubMed ID: 18046929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: a retrospective data analysis.
    Shenolikar RA; Balkrishnan R; Camacho FT; Whitmire JT; Anderson RT
    Clin Ther; 2006 Aug; 28(8):1199-1207. PubMed ID: 16982297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
    Barner JC
    Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
    Hansen RA; Farley JF; Droege M; Maciejewski ML
    Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
    Aquilante CL; Zhang W; McCollum M
    Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.
    Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
    Med Care; 2008 Nov; 46(11):1125-33. PubMed ID: 18953222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
    Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
    Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
    Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in Medicaid.
    Oladapo AO; Barner JC; Rascati KL; Strassels SA
    Clin Ther; 2012 Mar; 34(3):605-13. PubMed ID: 22386828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients.
    Cheong C; Barner JC; Lawson KA; Johnsrud MT
    Clin Ther; 2008 Oct; 30(10):1893-907. PubMed ID: 19014846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.
    Balkrishnan R; Rajagopalan R; Camacho FT; Huston SA; Murray FT; Anderson RT
    Clin Ther; 2003 Nov; 25(11):2958-71. PubMed ID: 14693318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs.
    Lokhandwala T; Smith N; Sternhufvud C; Sörstadius E; Lee WC; Mukherjee J
    J Med Econ; 2016; 19(3):203-12. PubMed ID: 26473990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes.
    Wu J; Seiber E; Lacombe VA; Nahata MC; Balkrishnan R
    Ann Pharmacother; 2011 Mar; 45(3):342-9. PubMed ID: 21325098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin.
    Shaya FT; Shin JY; Mullins D; Fatodu HO; Gu A; Saunders E
    J Natl Med Assoc; 2005 Apr; 97(4):493-7. PubMed ID: 15868769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.